The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.
Patients With Advanced Cancer With High TMB Show Favorable Outcomes on ICIs
May 5th 2023A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had low-TMB cancers.
Read More
Despite Potential Benefits, Barriers to CAR T-Cell Therapy for DLBCL Persist
April 13th 2023Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.
Read More
Early Recognition Key to Management of Immunotherapy Toxicities
April 11th 2023As much as immuno-oncology has been a leap forward, the ability to address immune-related adverse events is critical to making these therapies available in settings beyond academic centers; thus, the National Comprehensive Cancer Network offers clinical guidelines for management of toxicities.
Read More
DNA Sequencing Prior to HCT Identifies Patients at Risk of Poor AML Outcomes
April 8th 2023A study of patients with acute myeloid leukemia (AML) in first remission found that the presence of certain variants indicative of measurable residual disease ahead of allogeneic hematopoietic cell transplant (HCT) was associated with relapse and worse survival.
Read More
Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL
March 21st 2023A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).
Read More
Kentucky passes a bill to require insurers to cover biomarker tests for patients with cancer; CDC opioid guidelines updated in November may be too late for patients with chronic pain; the Environmental Protection Agency is proposing new limits to reduce dangerous human-manufactured chemicals in drinking water.
Read More
Lenvatinib Plus Pembrolizumab Shows Durable Efficacy Benefits vs Sunitinib in Renal Cell Carcinoma
March 8th 2023The extended follow-up results are consistent with the primary analysis of the CLEAR trial, supporting the increased efficacy of first-line lenvatinib plus pembrolizumab compared with sunitinib in patients with advanced renal cell carcinoma.
Read More
Oncolytic Virus Therapy Shows Promising Results in Early-Stage TNBC
February 22nd 2023Results from a phase 2 study suggests that the oncolytic virus talimogene laherparepvec has potential to improve therapy responses for patients undergoing neoadjuvant chemotherapy for triple-negative breast cancer (TNBC).
Read More
Study Suggests Second-line Axi-Cel Is Cost-effective vs Standard Care in R/R DLBCL
February 18th 2023Despite coming at a high cost, an analysis found that in some cases, chimeric antigen receptor T-cell therapy may be cost-effective compared with the standard of care in the second line or later for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Read More
Brexucabtagene Autoleucel Shows High Rate of Durable Response at 3 Years
February 9th 2023Chimeric antigen receptor T-cell therapy brexucabtagene autoleucel showed a rate of complete remission of 71% and a rate of complete remission with incomplete hematologic recovery of 56%, according to 3-year follow-up results.
Read More
Axi-cel Shows Improved Quality-Adjusted Survival Versus Standard of Care in LBCL
January 19th 2023A Q-TWiST analysis of ZUMA-7 trial data suggests that axicabtagene ciloleucel (axi-cel) in the second line is beneficial to quality-adjusted survival and is a viable option for patients with relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy.
Read More
From Lymphomas to Myeloma, Bispecific Antibodies Make a Big Splash at ASH
January 14th 2023At the 2022 annual meeting of the American Society of Hematology (ASH), customized cancer immunotherapy treatments now share the limelight with bispecific antibodies, which made news across disease states from large B-cell lymphoma to follicular lymphoma to multiple myeloma; as their name suggests, these treatments aim at 2 targets, increasing their potency against cancer.
Read More